傷口護理生物製劑市場機會、成長動力、產業趨勢分析及 2025-2034 年預測

2024 年全球傷口護理生物製劑市場價值為 22 億美元，預計 2025 年至 2034 年期間的複合年成長率為 5.2%。傷口護理生物製劑是一種生物工程治療方法，旨在增強人體的自然癒合反應，特別是針對慢性和無法癒合的傷口。這些解決方案透過加速組織修復，有助於最大限度地降低包括截肢在內的嚴重併發症的風險。慢性傷口盛行率的上升、手術數量的增加以及人口老化正在推動市場成長。燒傷和慢性傷口常見的地區對生物製劑的需求尤其高。醫療設施不足、感染風險較高等因素導致傷口癒合時間延長，進一步增加了對生物治療的依賴。此外，隨著老年人口的成長，壓瘡和糖尿病足潰瘍等疾病的發生率較高，對有效傷口癒合解決方案的需求也不斷增加。生物療法的進步也促進了市場的擴張，從而提高了治療效果。

根據產品類型，市場分為皮膚替代品和外用藥物。 2023 年整體市場價值為 21 億美元，其中皮膚替代品市場領先，2024 年將達到 14 億美元。這些產品提供結構支撐並促進慢性和急性傷口的組織再生。源自人類、動物或合成來源的皮膚替代品可縮短傷口閉合時間並最大限度地降低感染風險，使其成為治療的首選。慢性傷口的日益普及是推動該領域需求的關鍵因素，因為這些生物製劑顯著提高了癒合效率。

根據傷口類型，市場分為糖尿病足潰瘍、靜脈性腿部潰瘍、壓瘡、手術傷口、燒傷和其他傷口。手術傷口部分佔 2024 年市場總收入的 27%，預計到 2034 年將達到 8.775 億美元。預防手術部位感染、加速術後恢復和增強組織再生的需求日益成長，推動了對生物傷口護理產品的需求。全球手術數量的增加進一步加強了該領域的市場地位，因為生物製劑在減少併發症和改善患者預後方面發揮著至關重要的作用。

最終使用者部分包括醫院、門診手術中心和其他醫療機構。 2024 年，醫院佔據市場主導地位，收入佔有率為 43.8%，這得益於生物傷口護理解決方案被廣泛採用，用於治療複雜傷口，包括糖尿病足潰瘍、燒傷、壓瘡和術後傷口。先進皮膚替代品、生長因子療法和膠原蛋白敷料的使用日益增多，提高了癒合效果，同時降低了感染率。醫院內再生治療服務的擴展進一步支持了市場的成長。

美國傷口護理生物製劑市場取得了顯著成長，收入從 2023 年的 7.308 億美元成長到預計 2034 年的 12 億美元。慢性傷口負擔的增加和糖尿病患者的增加導致了這一上升趨勢。對先進傷口護理解決方案的需求不斷增加，加強了生物製劑在現代傷口管理中的作用。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 發展中和低度開發地區燒傷人數不斷增加
    • 全球老年人口不斷增加
    • 傷口護理生物製劑的技術進步
    • 政府關於傷口護理治療的措施激增
  • 產業陷阱與挑戰
    • 低度開發經濟體缺乏訓練有素的醫生
• 成長潛力分析
• 監管格局
• 技術格局
• 未來市場趨勢
• 差距分析
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：依產品類型，2021 年至 2034 年

• 主要趨勢
• 皮膚替代品
  • 生物
    • 同種異體移植
    • 異種移植
    • 其他生物皮膚替代品
  • 合成的
• 外用藥物

第6章：市場估計與預測：按傷口類型，2021 年至 2034 年

• 主要趨勢
• 糖尿病足潰瘍
• 靜脈性腿部潰瘍
• 壓瘡
• 手術傷口
• 燒傷
• 其他傷口類型

第7章：市場估計與預測：依最終用途，2021 年至 2034 年

• 主要趨勢
• 醫院
• 門診手術中心
• 其他最終用途

第8章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 沙烏地阿拉伯
  • 南非
  • 阿拉伯聯合大公國

第9章：公司簡介

• 3M
• Amnio Technology
• Avita Medical
• Convatec
• Derma Sciences
• Integra Life Sciences
• Kerecis
• Mimedx Group
• Mölnlycke Health Care
• Organogenesis
• Osiris Therapeutics
• Skye Biologics
• Smith & Nephew
• Solsys Medical
• Vericel Corporation
• Wright Medical

The Global Wound Care Biologics Market was valued at USD 2.2 billion in 2024 and is projected to expand at a CAGR of 5.2% from 2025 to 2034. Wound care biologics are bioengineered treatments designed to enhance the body's natural healing response, particularly for chronic and non-healing wounds. These solutions help minimize the risk of severe complications, including amputation, by accelerating tissue repair. The rising prevalence of chronic wounds, the increasing number of surgeries, and the aging population are driving market growth. The demand for biologics is particularly high in regions where burn injuries and chronic wounds are prevalent. Factors such as inadequate medical facilities and higher infection risks contribute to prolonged wound healing, further increasing the reliance on biologic treatments. Additionally, as the geriatric population grows, the need for effective wound healing solutions continues to rise due to the higher incidence of conditions such as pressure ulcers and diabetic foot ulcers. The market's expansion is also supported by advancements in biologic therapies that offer enhanced healing outcomes.

The market is segmented based on product type into skin substitutes and topical agents. The overall market was valued at USD 2.1 billion in 2023, with the skin substitutes segment leading at USD 1.4 billion in 2024. These products offer structural support and promote tissue regeneration in both chronic and acute wounds. Skin substitutes, derived from human, animal, or synthetic sources, reduce wound closure time and minimize infection risks, making them the preferred choice in treatment. The growing prevalence of chronic wounds is a key factor driving demand in this segment, as these biologics significantly enhance healing efficiency.

Based on wound type, the market is categorized into diabetic foot ulcers, venous leg ulcers, pressure ulcers, surgical wounds, burns, and other wounds. The surgical wounds segment accounted for 27% of the total market revenue in 2024 and is projected to reach USD 877.5 million by 2034. The increasing need to prevent surgical site infections, accelerate post-surgical recovery, and enhance tissue regeneration is fueling the demand for biologic wound care products. The rising number of surgeries performed globally is further strengthening the market position of this segment, as biologics play a crucial role in reducing complications and improving patient outcomes.

The end-user segment consists of hospitals, ambulatory surgical centers, and other healthcare facilities. Hospitals dominated the market with a 43.8% revenue share in 2024, driven by the widespread adoption of biologic wound care solutions for managing complex wounds, including diabetic foot ulcers, burns, pressure ulcers, and post-surgical wounds. The increasing use of advanced skin substitutes, growth factor therapies, and collagen-based dressings is enhancing healing outcomes while lowering infection rates. The expansion of regenerative therapy services within hospitals further supports market growth.

The U.S. wound care biologics market has seen significant growth, with revenues rising from USD 730.8 million in 2023 to a projected USD 1.2 billion by 2034. The increasing burden of chronic wounds and a rising diabetic population contribute to this upward trend. The demand for advanced wound care solutions continues to escalate, reinforcing the role of biologics in modern wound management.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising burn injuries in developing and underdeveloped regions
    • 3.2.1.2 Increasing geriatric population globally
    • 3.2.1.3 Technological advancements in wound care biologics
    • 3.2.1.4 Surge in government initiatives regarding wound care treatment
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Lack of trained physicians in underdeveloped economies
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Future market trends
• 3.7 Gap analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Skin substitutes
  • 5.2.1 Biological
    • 5.2.1.1 Allograft
    • 5.2.1.2 Xenograft
    • 5.2.1.3 Other biological skin substitutes
  • 5.2.2 Synthetic
• 5.3 Topical agents

Chapter 6 Market Estimates and Forecast, By Wound Type, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Diabetic foot ulcers
• 6.3 Venous leg ulcers
• 6.4 Pressure ulcers
• 6.5 Surgical wounds
• 6.6 Burns
• 6.7 Other wound types

Chapter 7 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Ambulatory surgical centers
• 7.4 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 3M
• 9.2 Amnio Technology
• 9.3 Avita Medical
• 9.4 Convatec
• 9.5 Derma Sciences
• 9.6 Integra Life Sciences
• 9.7 Kerecis
• 9.8 Mimedx Group
• 9.9 Mölnlycke Health Care
• 9.10 Organogenesis
• 9.11 Osiris Therapeutics
• 9.12 Skye Biologics
• 9.13 Smith & Nephew
• 9.14 Solsys Medical
• 9.15 Vericel Corporation
• 9.16 Wright Medical